HUTCHMED (HCM) said late Tuesday it has completed patient enrollment for its global Phase 3 study evaluating Orpathys in combination with Tagrisso for patients with a type of locally advanced or metastatic non-small cell lung cancer, who have progressed after treatment with Tagrisso.

The company said the last patient was randomized on Oct.31.

The drug developer said it enrolled 338 patients across more than 230 sites in 29 countries in a study that compares the Orpathys-Tagrisso combination against platinum-based chemotherapy.

The primary endpoint is progression-free survival as assessed by blinded independent central review, with secondary measures including overall survival, response rates, and safety, it added.

Topline results are expected in H1 2026, which could support global regulatory submissions if the data are favorable, the company said.